Baicalin reverses the impairment of synaptogenesis induced by dopamine burden via the stimulation of GABAAR-TrkB interaction in minimal hepatic encephalopathy

Psychopharmacology (Berl). 2018 Apr;235(4):1163-1178. doi: 10.1007/s00213-018-4833-8. Epub 2018 Feb 6.

Abstract

Background: It has been reported that D1 receptor (D1R) activation reduces GABAA receptor (GABAAR) current, and baicalin (BAI) displays therapeutic efficacy in diseases involving cognitive impairment.

Methods: We investigated the mechanisms by which BAI could improve DA-induced minimal hepatic encephalopathy (MHE) using immunoblotting, immunofluorescence, and co-immunoprecipitation.

Results: BAI did not induce toxicity on the primary cultured neurons. And no obvious toxicity of BAI to the brain was found in rats. DA activated D1R/dopamine and adenosine 3'5'-monophosphate-regulated phospho-protein (DARPP32) to reduce the GABAAR current; BAI treatment did not change the D1R/DARPP32 levels but blocked DA-induced reduction of GABAAR levels in primary cultured neurons. DA decreased the interaction of GABAAR with TrkB and the expression of downstream AKT, which was blocked by BAI treatment. Moreover, BAI reversed the decrease in the expression of GABAAR/TrkB/AKT and prevented the impairment of synaptogenesis and memory deficits in MHE rats.

Conclusions: These results suggest that BAI has neuroprotective and synaptoprotective effects on MHE which are not related to upstream D1R/DARPP32 signaling, but to the targeting of downstream GABAAR signaling to TrkB.

Keywords: Baicalin; DARPP32; Dopamine; GABAAR; Minimal hepatic encephalopathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Animals, Newborn
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Cells, Cultured
  • Dopamine / metabolism*
  • Dopamine / pharmacology
  • Dose-Response Relationship, Drug
  • Flavonoids / pharmacology*
  • Flavonoids / therapeutic use
  • Hepatic Encephalopathy / drug therapy
  • Hepatic Encephalopathy / metabolism*
  • Neurons / drug effects
  • Neurons / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, trkB / metabolism*
  • Receptors, Dopamine D1 / metabolism
  • Receptors, GABA-A / metabolism*
  • Synapses / drug effects
  • Synapses / metabolism*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Flavonoids
  • Receptors, Dopamine D1
  • Receptors, GABA-A
  • baicalin
  • Ntrk2 protein, rat
  • Receptor, trkB
  • Dopamine